Advanced Health Limited, together with its subsidiaries, provides short-procedure surgical services and diagnostic procedures through a network of day hospitals.
Price History & Performance
|Historical stock prices|
|Current Share Price||R0.39|
|52 Week High||R0.22|
|52 Week Low||R0.51|
|1 Month Change||-2.50%|
|3 Month Change||-4.88%|
|1 Year Change||30.00%|
|3 Year Change||-9.30%|
|5 Year Change||-74.68%|
|Change since IPO||-71.74%|
Recent News & Updates
Advanced Health's (JSE:AVL) Returns On Capital Are Heading Higher
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...
Does Advanced Health (JSE:AVL) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Here's What To Make Of Advanced Health's (JSE:AVL) Decelerating Rates Of Return
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
Read This Before Selling Advanced Health Limited (JSE:AVL) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
|AVL||ZA Healthcare||ZA Market|
Return vs Industry: AVL exceeded the ZA Healthcare industry which returned 25.8% over the past year.
Return vs Market: AVL exceeded the ZA Market which returned 19.9% over the past year.
Stable Share Price: AVL is more volatile than 75% of ZA stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: AVL's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of ZA stocks.
About the Company
|2013||152||Gerhard van Emmenis||https://www.advancedhealth.co.za|
Advanced Health Limited, together with its subsidiaries, provides short-procedure surgical services and diagnostic procedures through a network of day hospitals. It offers plastic surgery, such as blepharoplasty, breast augmentation, facelift, labiaplasty, liposuction, mastopexy, rhinoplasty, and otoplasty; dermatological services, including cauterization nevus, lipoma, mole and wart removal, and scar excision/ revision surgery; urology services, such as circumcision, cystoscopy and ureteral dilation, inguinal hernia repair, prostate biopsy, renal calcultus removal and stent insertion, scope and pyelogram, vasectomy, and vasostomy; and ophthalmology services, including cataract, corneal, laser surgery, intraocular injection, posterior and anterior vitrectomy, tear ducts repair, and pterygium and removal; and gynecological services, such as cauterization, cervical cerclage and lletz, dilatation and curetation, drainage of bartholin cyst, endometrial ablation, hysteroscopy, insertion intrauterine device, labiaplasty, laparoscopic sterilization, and cyst removal. The company also provides orthopedic services, including arthroscopy, bunionectomy, carpal tunnel release, ganglionectomy, insertion/removal of k wires, toenail resection, achille tendon release, pins and plates removal, peripheral nerve neuroplasty, trigger finger release, fracture reduction, and pain management; ENT services, such as adenoidectomy, antrostomy, bone anchor external hearing device, cochlear implant, diagnostic proof puncture, endoscopy, electro cauterization, myringotomy, nose fracture reduction, rhinoplasty, septoplasty, tonsillectomy, turbinectomy, and tympanoplasty; and maxillofacial and dental services, including apisectomy, extraction, frenectomie, gingival graft, orthodontic attachment, sinus augmentation, and teeth removal.
Advanced Health Fundamentals Summary
|AVL fundamental statistics|
Is AVL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AVL income statement (TTM)|
|Cost of Revenue||R348.41m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.036|
|Net Profit Margin||-2.61%|
How did AVL perform over the long term?See historical performance and comparison
Is Advanced Health undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AVL (ZAR0.39) is trading below our estimate of fair value (ZAR2.15)
Significantly Below Fair Value: AVL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AVL is unprofitable, so we can't compare its PE Ratio to the African Healthcare industry average.
PE vs Market: AVL is unprofitable, so we can't compare its PE Ratio to the ZA market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVL is overvalued based on its PB Ratio (3.6x) compared to the XF Healthcare industry average (2.8x).
How is Advanced Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Advanced Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Advanced Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVL is currently unprofitable.
Growing Profit Margin: AVL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVL is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.
Accelerating Growth: Unable to compare AVL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVL is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (4.5%).
Return on Equity
High ROE: AVL has a negative Return on Equity (0.32%), as it is currently unprofitable.
How is Advanced Health's financial position?
Financial Position Analysis
Short Term Liabilities: AVL's short term assets (ZAR214.4M) exceed its short term liabilities (ZAR184.4M).
Long Term Liabilities: AVL's short term assets (ZAR214.4M) do not cover its long term liabilities (ZAR562.1M).
Debt to Equity History and Analysis
Debt Level: AVL's debt to equity ratio (113.5%) is considered high.
Reducing Debt: AVL's debt to equity ratio has increased from 33.3% to 113.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable AVL has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: AVL is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 37.5% per year.
What is Advanced Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVL's dividend in 3 years as they are not forecast to pay a notable one for the ZA market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Gerhard van Emmenis (59 yo)
Mr. Gerhard Jacobus van Emmenis serves as Chief Executive Officer and Director at Advanced Health Limited since August 1, 2019. Mr Van Emmenis joins the day-hospital group from Bonitas, where he served as...
CEO Compensation Analysis
Compensation vs Market: Gerhard's total compensation ($USD196.73K) is below average for companies of similar size in the ZA market ($USD283.52K).
Compensation vs Earnings: Gerhard's compensation has been consistent with company performance over the past year.
Experienced Board: AVL's board of directors are considered experienced (7.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 73.2%.
Advanced Health Limited's employee growth, exchange listings and data sources
- Name: Advanced Health Limited
- Ticker: AVL
- Exchange: JSE
- Founded: 2013
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: R194.526m
- Shares outstanding: 498.78m
- Website: https://www.advancedhealth.co.za
Number of Employees
- Advanced Health Limited
- Building 3
- 2nd Floor
- South Africa
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 21:04|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.